Scarica l'app Stockscreener
140.98
5.56%
-8.30
Pre-mercato:
139.49
-1.49
-1.06%
Precedente Chiudi:
$149.28
Aprire:
$146.33
Volume 24 ore:
1.01M
Relative Volume:
0.95
Capitalizzazione di mercato:
$7.21B
Reddito:
$4.06B
Utile/perdita netta:
$413.08M
Rapporto P/E:
17.60
EPS:
8.01
Flusso di cassa netto:
$560.48M
1 W Prestazione:
-10.81%
1M Prestazione:
-13.77%
6M Prestazione:
-25.64%
1 anno Prestazione:
-45.63%
Intervallo 1D:
$138.70
$146.33
Intervallo di 1 settimana:
$138.70
$158.71
Portata 52W:
$138.70
$264.70
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
140.98 | 7.21B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
470.03 | 177.32B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
197.90 | 141.59B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
410.76 | 33.29B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
109.67 | 31.28B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
167.69 | 29.57B | 15.41B | 1.37B | 2.11B | 7.50 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-03 | Aggiornamento | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Downgrade | UBS | Buy → Neutral |
| 2024-11-18 | Downgrade | CLSA | Hold → Underperform |
| 2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
| 2024-10-23 | Iniziato | CLSA | Underperform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Sell |
| 2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
| 2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Downgrade | Argus | Buy → Hold |
| 2024-06-07 | Iniziato | Mizuho | Neutral |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-09-13 | Iniziato | TD Cowen | Market Perform |
| 2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
| 2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-12 | Downgrade | Jefferies | Buy → Hold |
| 2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Iniziato | Guggenheim | Neutral |
| 2022-04-25 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-07 | Iniziato | Stephens | Overweight |
| 2022-02-17 | Reiterato | BofA Securities | Buy |
| 2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-17 | Reiterato | Deutsche Bank | Buy |
| 2022-02-17 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-17 | Reiterato | UBS | Buy |
| 2021-08-05 | Ripresa | Credit Suisse | Neutral |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2020-04-21 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Iniziato | Deutsche Bank | Buy |
| 2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-01-08 | Iniziato | Wells Fargo | Overweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Iniziato | SVB Leerink | Outperform |
| 2019-04-30 | Ripresa | Evercore ISI | Outperform |
| 2018-12-14 | Iniziato | Deutsche Bank | Buy |
| 2018-10-09 | Iniziato | UBS | Neutral |
| 2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks? - MSN
Human Microbiome Sequencing Market Key Players Analysis - openPR.com
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Integrates Akron Bio’s CSS Line of Liquid Cytokines - Contract Pharma
Charles River Labs stock hits 52-week low at $150.19 By Investing.com - Investing.com Australia
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating - MarketScreener
Charles River Labs stock hits 52-week low at $150.19 - Investing.com
Mawer Investment Management Ltd. Buys 5,769 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Genetic Toxicology Testing Market To Witness Huge Gains Over - openPR
Biopharma Layoffs Roundup - Contract Pharma
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform - BioSpace
Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform - Marketscreener.com
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica - Business Wire
Why Charles River Laboratories International, Inc. (CRL) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Goldman Sachs Downgrades Charles River Laboratories International (CRL) - MSN
Demystifying Charles River: Insights From 10 Analyst Reviews - Benzinga
Icon stock, Charles River stock downgraded at Goldman (CRL) - Seeking Alpha
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 - Investing.com India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Charles River Laboratories International to Neutral From Buy, Adjusts Price Target to $170 From $190 - Marketscreener.com
Jefferies maintains Charles River Labs stock hold, price target at $169 - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For November 21st - Nasdaq
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo Finance
Earnings call transcript: Charles River Labs beats Q4 2024 forecasts By Investing.com - Investing.com UK
Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171? - Simply Wall St
Charles River Laboratories to Present at Barclays Global Healthcare Conference - BioSpace
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Mutual of America Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Smartleaf Asset Management LLC Increases Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN
Charles River announces agreement with Singapore General Hospital - SelectScience
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Citigroup - Defense World
Reasons to Retain Charles River Stock in Your Portfolio for Now - Yahoo Finance
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Charles River Laboratories Shares Rise After Citigroup Upgrade -March 04, 2025 at 02:53 pm EST - Marketscreener.com
Citi raises Charles River stock rating, lifts target to $175 - Investing.com
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.14%
1.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):